The DayOne Accelerator Program for Healthtech Startups is now accepting applications for its three-month hybrid program based in Basel, Switzerland, according to a recent announcement. The program targets early-stage healthtech and techbio ventures developing solutions to support pharmaceutical research and development. The application period is open until the deadline of May 31, 2026.
This initiative provides a structured, equity-free, and fee-free opportunity for emerging companies in the life sciences sector. For startups operating at the pre-seed to Series A stage, the program offers access to potential non-dilutive funding and support without requiring them to give up ownership. The immediate consequence is that eligible global startups can now apply for a spot in the cohort, which includes financial support for travel and the possibility of follow-on funding after completion.
What We Know So Far
- The DayOne Accelerator is inviting applications from healthtech and techbio startups with a focus on supporting pharmaceutical R&D, according to a report from www2.fundsforngos.org.
- The program is structured as a three-month hybrid accelerator based in Basel, Switzerland, and is offered on an equity-free and fee-free basis, the announcement states.
- Eligibility is open to global startups from pre-seed to Series A funding stages, provided they have raised less than USD 10 million in total dilutive funding.
- Selected ventures may receive up to CHF 1,000 in travel support for an initial bootcamp and could be eligible for up to CHF 50,000 in post-program non-dilutive funding.
- The final deadline for all applications to the DayOne Accelerator program is May 31, 2026.
